Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aligos Therapeutics (ALGS) EBIT (2021 - 2025)

Historic EBIT for Aligos Therapeutics (ALGS) over the last 5 years, with Q3 2025 value amounting to -$28.4 million.

  • Aligos Therapeutics' EBIT fell 4088.22% to -$28.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$86.7 million, marking a year-over-year increase of 830.34%. This contributed to the annual value of -$89.2 million for FY2024, which is 116.54% down from last year.
  • Latest data reveals that Aligos Therapeutics reported EBIT of -$28.4 million as of Q3 2025, which was down 4088.22% from -$18.6 million recorded in Q2 2025.
  • Over the past 5 years, Aligos Therapeutics' EBIT peaked at -$18.6 million during Q2 2025, and registered a low of -$37.9 million during Q4 2021.
  • For the 5-year period, Aligos Therapeutics' EBIT averaged around -$24.7 million, with its median value being -$22.7 million (2022).
  • Its EBIT has fluctuated over the past 5 years, first skyrocketed by 4269.99% in 2022, then plummeted by 4088.22% in 2025.
  • Quarter analysis of 5 years shows Aligos Therapeutics' EBIT stood at -$37.9 million in 2021, then surged by 40.23% to -$22.7 million in 2022, then fell by 14.62% to -$26.0 million in 2023, then rose by 20.9% to -$20.6 million in 2024, then tumbled by 37.92% to -$28.4 million in 2025.
  • Its EBIT was -$28.4 million in Q3 2025, compared to -$18.6 million in Q2 2025 and -$19.2 million in Q1 2025.